 |
 |
Hi All, There are studies still recruiting... CLINICAL TRIAL OF AN EXPERIMENTAL MEDICATION FOR PARKINSON’S DISEASE This is a controlled clinical trial of an experimental drug, Rasagiline Mesylate. Rasagiline Mesylate is a novel type B monoamine oxidase inhibitor that may be of benefit for early Parkinson’s disease patients. In this clinical trial, the drug will be studied to determine the best tolerated dosage and its impact on the features of Parkinson’s disease. Qualifications: Diagnosis of idiopathic Parkinson’s disease not taking or requiring any antiparkinsonian medication. Involvement: The study will last 1 year and include 11 office visits. Contact Information: Cari DeLoa at (415)476-9276 http://www.gcrc.ucsf.edu/recruitment.htm [log in to unmask]